203 related articles for article (PubMed ID: 31648478)
21. [Expression of Tim-3 on Peripheral CD56(+) NK Cells and ItsCorrelation with Liver Fibrosis in Patients withAdvanced Schistosomiasis].
WU QW; ZHU X; FU X; YANG JS; CAO ZG; PU C
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2015 Oct; 33(5):346-50. PubMed ID: 26931038
[TBL] [Abstract][Full Text] [Related]
22. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Rakova J; Truxova I; Holicek P; Salek C; Hensler M; Kasikova L; Pasulka J; Holubova M; Kovar M; Lysak D; Kline JP; Racil Z; Galluzzi L; Spisek R; Fucikova J
Oncoimmunology; 2021 Mar; 10(1):1889822. PubMed ID: 33758676
[TBL] [Abstract][Full Text] [Related]
23. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
24. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT
Zeng X; Yao D; Liu L; Zhang Y; Lai J; Zhong J; Zha X; Lu Y; Jin Z; Chen S; Li Y; Xu L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):456-464. PubMed ID: 34811925
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
26. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
Eckel AM; Cherian S; Miller V; Soma L
Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities.
Ho X; Fook-Chong S; Linn YC
Leuk Lymphoma; 2014 Feb; 55(2):342-8. PubMed ID: 23550989
[TBL] [Abstract][Full Text] [Related]
28. Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An
Astaneh M; Rezazadeh H; Hossein-Nataj H; Shekarriz R; Zaboli E; Shabani M; Asgarian-Omran H
J Cancer Res Ther; 2022; 18(3):704-711. PubMed ID: 35900543
[TBL] [Abstract][Full Text] [Related]
29. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract][Full Text] [Related]
30. [Detection and Analysis of T Lymphocyte Subsets and B Lymphocytes in Patients with Acute Leukemia].
Cheng J; Ma HZ; Zhang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):327-330. PubMed ID: 30998133
[TBL] [Abstract][Full Text] [Related]
31. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
[TBL] [Abstract][Full Text] [Related]
32. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells.
Gonçalves Silva I; Yasinska IM; Sakhnevych SS; Fiedler W; Wellbrock J; Bardelli M; Varani L; Hussain R; Siligardi G; Ceccone G; Berger SM; Ushkaryov YA; Gibbs BF; Fasler-Kan E; Sumbayev VV
EBioMedicine; 2017 Aug; 22():44-57. PubMed ID: 28750861
[TBL] [Abstract][Full Text] [Related]
33. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.
Vidriales MB; Orfao A; López-Berges MC; González M; Hernandez JM; Ciudad J; López A; Moro MJ; Martínez M; San Miguel JF
Ann Hematol; 1993 Nov; 67(5):217-22. PubMed ID: 7694663
[TBL] [Abstract][Full Text] [Related]
34. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
Yang L; Feng Y; Wang S; Jiang S; Tao L; Li J; Wang X
Int Immunopharmacol; 2021 Oct; 99():107965. PubMed ID: 34273636
[TBL] [Abstract][Full Text] [Related]
35. [Research on the negative immune regulation of NK cells in patients with primary immune thrombocytopenia].
Zhang YJ; Qu W; Liu H; Wang YH; Liu CY; Li LJ; Wang HQ; Fu R; Xing LM; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2017 May; 38(5):399-403. PubMed ID: 28565739
[No Abstract] [Full Text] [Related]
36. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis.
Hou N; Zhao D; Liu Y; Gao L; Liang X; Liu X; Gai X; Zhang X; Zhu F; Ni M; Zhang Y; Sun W; Ma C
Atherosclerosis; 2012 May; 222(1):67-73. PubMed ID: 22387059
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia.
Wu Z; Ou J; Liu N; Wang Z; Chen J; Cai Z; Liu X; Yu X; Dai M; Zhou H
Cancer Med; 2023 Apr; 12(7):8956-8969. PubMed ID: 36545697
[TBL] [Abstract][Full Text] [Related]
38. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract][Full Text] [Related]
39. The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer.
Wang Z; Zhu J; Gu H; Yuan Y; Zhang B; Zhu D; Zhou J; Zhu Y; Chen W
Immunol Invest; 2015; 44(6):578-89. PubMed ID: 26214042
[TBL] [Abstract][Full Text] [Related]
40. IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway.
Wu K; Zhao H; Xiu Y; Li Z; Zhao J; Xie S; Zeng H; Zhang H; Yu L; Xu B
Int Immunopharmacol; 2019 Apr; 69():136-142. PubMed ID: 30708194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
